Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) ELISA Kits

CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C19 Antibodies (39) and CYP2C19 Proteins (3) and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
CYP2C19 1557 P33261
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top CYP2C19 ELISA Kits at

Showing 3 out of 19 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Supplier Delivery Price Details
Rat 0.28 ng/mL 0.78-50 ng/mL 96 Tests Log in to see 13 to 16 Days
Human 0.264 ng/mL 0.62 ng/mL - 40 ng/mL 96 Tests Log in to see 13 to 16 Days
Human 0056 ng/mL 0.156 ng/mL - 10 ng/mL   96 Tests Log in to see 15 to 17 Days

More ELISA Kits for CYP2C19 Interaction Partners

Human Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) interaction partners

  1. Esomeprazole did not affect that of prasugrel irrespective of CYP2C19 genotype.

  2. The effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP.

  3. It was found that progesterone (P4) modulated the both kinetic and equilibrium constants of CYB5A/CYP17A1 and CYB5/CYP21A2 complex formation and complexes, while not affecting the CYB5A/CYP2C19 interaction.

  4. CYP2C19 polymorphism affects residual platelet reactivity during maintenance with prasugrel in Korean outpatients.

  5. The carriage of CYP2C19*2 or *3 mutant allele was significantly associated with attenuated platelet response to clopidogrel and increased clopidogrel resistance risk.

  6. These results highlight that CYP2C19*2, along with diabetes, and use of proton pump inhibitor and statin are important factors jointly associated with variability in clinical response to Dual antiplatelet therapy following acute coronary syndrome in Egyptians

  7. Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

  8. The CYP2C19 genotype had a substantial impact on exposure and therapeutic failure of escitalopram, as measured by switching of antidepressant therapy. The results support the potential clinical utility of CYP2C19 genotyping for individualization of escitalopram therapy.

  9. CYP2C19 genetic polymorphism may be associated with the increased risk of cerebral infarction in the elderly

  10. study characterizes two new haplotypes in Scandinavian subjects, each containing two clinically important single nucleotide polymorphisms in CYP2C19 and CYP2C8, respectively

  11. In patients with high-risk TIA or minor ischemic stroke CYP2C19 loss of function SNP was associated with increased risk of adverse cerebrovascular outcomes in patients in the lowest quintile of estimated glomerular filtration rate.

  12. carriage of CYP2C19*2 polymorphism, in diabetes mellitus patients, might be a potential predictor of persisting clopidogrel platelet reactivity in these high-risk individuals

  13. We found no evidence to support a clinically meaningful role of CYP2C19 polymorphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genotype status should not be included in clinical decisions on tamoxifen treatment.

  14. The CYP2C19 polymorphism is associated with the frequency of major adverse cardiovascular events, but is not related to the incidence of bleeding after percutaneous coronary intervention in Japanese patients receiving clopidogrel.

  15. CYP2C19 genotype-based dosing combined with therapeutic drug monitoring will support individualization of Voriconazole dosing, and potentially will minimize toxicity and maximize therapeutic efficacy

  16. The combined genotype of CYP3A5*1/*3 and CYP2C19*1/*1 was associated with a low level of VASP phosphorylation, while either genotype was not. A multivariate analysis showed that high residual platelet reactivity during the cilostazol treatment, which was defined by a low response of platelet VASP phosphorylation to cilostazol, was an independent risk factor for the recurrence of thrombotic events.

  17. Minor allele frequencies (MAF) in a Puerto Rican population were 46% for PON1 (rs662), 41% for ABCB1 (rs1045642), 14% for CYP2C19*17, 13% for CYP2C19*2, 12% for P2RY12-H2 and 0.3% for CYP2C19*4. No carriers of the CYP2C19*3 variants were detected. All alleles and genotype proportions were found to be in HardyWeinberg equilibrium (HWE).

  18. The frequency distribution of alleles CYP2C19 in Yakuts is between that in the representatives of Mongoloid and Caucasian races, which can be explained by the history of forming the population of this particular region.

  19. The CYP2C19 phenotype is not predicted by the number of functional alleles of CYP2C19 and CYP3A4 genes.

  20. CYP2C19*2 genotype-guided antiplatelet treatment remained a cost-effective strategy.

CYP2C19 Antigen Profile

Antigen Summary

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

Gene names and symbols associated with CYP2C19

  • cytochrome P450 family 2 subfamily C member 19 (CYP2C19) antibody
  • cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) antibody
  • cytochrome P450 2C19 (CYP2C19) antibody
  • CPCJ antibody
  • CYP2C antibody
  • P450C2C antibody
  • P450IIC19 antibody

Protein level used designations for CYP2C19

(R)-limonene 6-monooxygenase , (S)-limonene 6-monooxygenase , (S)-limonene 7-monooxygenase , CYPIIC17 , CYPIIC19 , S-mephenytoin 4-hydroxylase , cytochrome P-450 II C , cytochrome P450 2C19 , cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19 , cytochrome P450-11A , cytochrome P450-254C , flavoprotein-linked monooxygenase , mephenytoin 4'-hydroxylase , mephenytoin 4-hydroxylase , microsomal monooxygenase , xenobiotic monooxygenase , cytochrome P450 2C

1557 Homo sapiens
510380 Bos taurus
100534653 Ovis aries
Selected quality suppliers for CYP2C19 (CYP2C19) ELISA Kits
Did you look for something else?